
Sweetener in DOZENS of 'healthy' low-calorie foods spikes risk of stroke, experts discover - as cases soar in young people
Erythritol, which is also commonly found in flavoured waters and popular diet products like Halo Top ice cream—has already been linked to digestive issues and heart problems.
Now, scientists at the University of Colorado say even small amounts of the substance may promote blood clotting and inflammation, potentially raising the risk of cardiovascular events such as heart attacks and strokes.
Experts warned the findings could help explain the sharp rise in premature deaths from cardiovascular disease seen over the past decade.
The study, led by vascular health specialist Professor Christopher DeSouza, involved exposing human brain cells to erythritol at levels equivalent to those found in a standard sugar-free drink such as Vitaminwater and Monster.
Within three hours, the cells showed signs of inflammation and an increased tendency to clot.
'Our study adds to the growing body of evidence suggesting that so-called "safe" non-nutritive sweeteners may come with hidden health risks,' said Prof DeSouza.
'Not only that, it demonstrates how erythritol in particular may raise stroke risk.'
A previous study involving more than 4,000 people found that those with the highest levels of erythritol in their blood were significantly more likely to suffer a heart attack or stroke within three years.
In the new study, Professor Christopher DeSouza and colleagues at the University of Colorado exposed human brain cells to erythritol at concentrations similar to those found in a standard sugar-free drink such as Vitaminwater.
Within three hours, the cells showed clear signs of inflammation and clotting. They also produced significantly less nitric oxide—a molecule that helps relax blood vessels—and more proteins that cause blood vessels to constrict.
'Big picture, if your vessels are more constricted and your ability to break down blood clots is lowered, your risk of stroke goes up,' said study co-author Auburn Berry.
Professor DeSouza added: 'Our study adds to the growing body of evidence suggesting that so-called "safe" non-nutritive sweeteners may come with hidden health risks.
'Not only that, it demonstrates how erythritol in particular may raise stroke risk.'
The erythritol-treated cells also produced more free radicals—unstable molecules which are known to cause damage to the DNA inside cells if they build up.
This in turn can cause oxidative stress which has been linked with heart disease, dementia and even cancer.
While the researchers only tested brain cells in a lab and used a dose equivalent to a single serving of erythritol, Professor DeSouza warned that people who consume multiple servings a day—via diet drinks, protein bars or low-calorie desserts—could face a higher risk.
He urged the public to be mindful of their intake, warning: 'These sweeteners come with a plethora of negative health consequences.'
However, the team acknowledged this was a key limitation of the study, and further research is needed to confirm whether erythritol has similar effects in the human body.
Erythritol was first approved by the US Food and Drug Administration (FDA) in 2001.
It is typically made by fermenting corn and is found in hundreds of products as a low-calorie sugar substitute.
It mimics the taste of sugar but isn't metabolised in the same way—meaning it contains virtually no calories.
For that reason, it has become a popular choice among dieters and people with diabetes trying to control blood sugar levels.
But erythritol is also naturally produced in small amounts by the body.
Experts say that consuming it in high levels—through both processed products and natural sources like fruit and vegetables—could potentially push levels into the danger zone.
Concerns about artificial sweeteners, widely added to everything from fizzy drinks to 'healthy' snacks, have been building for years amid mounting evidence they may not be as harmless as once believed.
But critics highlight such studies are only observational, meaning they are unable to prove artificial sweeteners are the culprit and cannot rule out other external factors being to blame.
Worries were heightened in 2023 after the World Health Organisation controversially classified the artificial sweetener aspartame, found in drinks like Diet Coke, as 'possibly carcinogenic to humans'.
However, the UN agency ruled it only posed a risk to those who consumed massive amounts and that an 11 stone (70kg) adult could safely drink about 14 cans a day.
But now, Taiwanese researchers have warned that children who consume a diet packed with sweeteners may be at higher risk of reaching puberty earlier.
They found that high levels of the additives could trigger central precocious puberty—where the first signs of puberty typically emerge before the age of eight in girls and nine in boys.
Higher consumption of 'added sugars', meaning those above the natural content of a food or drink item, was also linked with an earlier puberty—increasing the risk of depression, diabetes and even cancer.
MailOnline has previously reported that the number of under-40s treated by the NHS for heart attacks is also climbing, with soaring obesity rates and related health issues believed to be key drivers.
In the UK, around 420 people of working age die of as a result of heart disease each week, totalling an alarming 21,975 a year.
Cardiovascular disease is America's number one killer and nearly 1million people die of it every year.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
12 minutes ago
- The Independent
WeightWatchers boss says ‘exciting work to do' amid impact of weight loss jabs
WeightWatchers was slower to adapt to the emergence of anti-obesity jabs than rivals, its boss has admitted, as the 62-year-old brand strives to catch up with rapidly evolving attitudes towards weight loss. Tara Comonte, chief executive of the US-based business, said it had a lot of work to do after going through a 'reset'. WeightWatchers recently announced it had emerged from bankruptcy after writing off a portion of the 1.15 billion US dollar (£860 million) debt on its balance sheet. It came as the business was competing with the emergence of GLP-1s – the scientific term for weight loss jabs, which work by reducing food cravings – and a new wave of apps and advice spreading on social media. Ms Comonte told the PA news agency that it 'wasn't as quick to medical weight loss solutions' as some other firms in the US, notably so-called 'telehealth' businesses that offer healthcare remotely. WeightWatchers, which runs some 20,000 workshops each month globally, is now 'at the beginning of the journey' towards forging a new place in the industry and meeting demand from current and future members, Ms Comonte said. 'This whole industry is going through somewhat of a reset and we have exciting work to do,' she told the PA news agency. 'This is a moment where, possibly more than ever before, people are talking about weight, and weight health… where people are seeking more education than ever before, and there are more voices than ever before.' Ms Comonte said the brand was known for 'trust and science' and it was important to harness that 'as there are more and more voices in the ecosystem'. WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app. It forms part of its efforts to muscle into the market by offering behavioural strategies and community-based support to people using or coming off the medication. 'There's no 'us and them' anymore,' Ms Comonte told PA, hitting back at weight loss jabs often being pitted as rivals to its model. Dr Kim Boyde, WeightWatchers' newly appointed chief medical officer, said not all its members will want or need weight loss medication – but stressed that it was 'imperative' the programme offers it to those that might benefit. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.


Reuters
an hour ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.


Reuters
3 hours ago
- Reuters
Roche to test if new drug can prevent Alzheimer's disease, Bloomberg News reports
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to test whether an experimental medicine can prevent Alzheimer's disease symptoms in high-risk people, Bloomberg News reported on Sunday. The new late-stage study will target people who are at risk of cognitive decline and aim to slow down the emergence of symptoms or prevent them fully, the report said, citing a statement. The new pre-clinical study is the third largest late-stage trial that the company has announced for its drug trontinemab, which uses an experimental technology called brain shuttle to ferry medicine past the protective blood-brain barrier, according to the report. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently with Lilly's Alzheimer's drug Kisunla getting recommendation from the European Medicines Agency (EMA) last week. Reuters could not immediately verify the report. Roche did not immediately respond to a request for a comment. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also carry hefty price tags and the risk of serious brain swelling and bleeding.